Colpotrophine (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022

Date: July 31, 2013
Pages: 33
Price:
US$ 3,495.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CD517B50C0CEN
Leaflet:

Download PDF Leaflet

Colpotrophine (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022
Summary

Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade, it is expected to undergo a considerable change between 2012 and 2022. This market has historically had a large untreated population due to: low diagnosis rates, safety issues with the existing therapies, and poor patient compliance. Since the mainstay estrogen-based therapies are associated with causing elevated risk for breast cancer, endometrial cancer, and stroke, many women go untreated.

Theramex’s Colpotrophine (promestriene) consists of a synthetic estrogen that is used exclusively for local application and acts on the lining of the vagina and vulva. This product is indicated for the treatment of VVA, vulvar itching, vulvar dryness, and vulvar kraurosis. It is also used for treating delayed vaginal healing postpartum. Colpotrophine is available in two dosage forms: as a cream and a capsule.

Scope
  • Overview of PVA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Colpotrophine including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Colpotrophine for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for PVA
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Colpotrophine performance
  • Obtain sales forecast for Colpotrophine from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)
1 TABLE OF CONTENTS

1.1 List of Tables

2 INTRODUCTION

2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 DISEASE OVERVIEW

3.1 Etiology and Pathophysiology
  3.1.1 Etiology
  3.1.2 Pathophysiology
  3.1.3 Prognosis
  3.1.4 Quality of Life
3.2 Symptoms

4 DISEASE MANAGEMENT

4.1 Treatment Overview
4.2 Treatment Guidelines
4.3 Disease Management

5 COMPETITIVE ASSESSMENT

5.1 Overview
5.2 Strategic Competitor Assessment

6 COLPOTROPHINE (PROMESTRIENE VAGINAL CREAM/OVULE)

6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast

7 APPENDIX

7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
  7.4.1 Diagnosed postmenopausal atrophy patients
  7.4.2 Percent Drug-Treated Patients
  7.4.3 General Pricing Assumptions
  7.4.4 Individual Drug Assumptions
  7.4.5 Generic Erosion
7.5 Physicians and Specialists Included in This Study
7.6 About the Authors
  7.6.1 Author
  7.6.2 Epidemiologists
  7.6.3 Global Director of Epidemiology and Clinical Trials Analysis
  7.6.4 Director of Oncology, Hematology and Gender Health
  7.6.5 Global Head of Healthcare
7.7 About GlobalData
7.8 Disclaimer

LIST OF TABLES

Table 1: Symptoms of PVA
Table 2: Treatment Guidelines for PVA
Table 3: Most Prescribed Drugs for PVA by Class in the Global Markets, 2012
Table 4: Leading Treatments for PVA, 2012
Table 5: Product Profile - Colpotrophine
Table 6: Colpotrophine SWOT Analysis, 2012
Table 7: Global Sales Forecasts ($m) for Colpotrophine, 2012-2022

Ask Your Question

Colpotrophine (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: